Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13856314 | 0.68 | DRD2 (0.39) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL6582488 | 0.68 | DRD2 (0.36) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL6580376 | 0.68 | DRD2 (0.40) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL8803236 | 0.67 | DRD2 (0.42) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL4496862 | 0.66 | DRD2 (0.56) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL6585440 | 0.66 | DRD1 (0.44) | PRCPDRD2DRD4MAPTALDH1A1 | |
| SCHEMBL4504545 | 0.66 | DRD2 (0.47) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL6582387 | 0.65 | DRD2 (0.50) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL18873961 | 0.62 | DRD2 (0.40) | DRD2DRD4MAPTALDH1A1AR | |
| SCHEMBL6580379 | 0.61 | DRD2 (0.36) | DRD2DRD4MAPTALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146044-B1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6743818-B2 | TREATING ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-06-01 | — | — | US | disclosed |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | PEGLION JEAN-LOUIS (FR) | 2003-02-13 | — | — | US | disclosed |
| US-6452015-B2 | FOR TREATMENT OF ANXIETY, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, IMPULSIVE DISORDERS, DRUG ABUSE, COGNITIVE DISORDERS, PSYCHOSES, DEPRESSION AND MOOD DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-11-22 | — | — | US | disclosed |
| EP-1146044-A1 | CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044426-A1 | Cyclobutaindolecarboxamide compounds | HRH4, HTR4, CNR1 | PRCP 2917/4885DRD2 437/4885DRD4 126/4885 |
| US-20030032812-A1 | Cyclobutaindolecarboxamide compounds | CYP2W1, HRH4, CNR1 | PRCP 2215/4885DRD2 606/4885DRD4 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.